SC
MNTA

Samlyn Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Samlyn Capital’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-264,000
Closed -$3.97M – 172
2016
Q4 		$3.97M Buy
+264,000
New +$3.49M 0.09% 109

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Samlyn Capital's MNTA Position: Q1 2017 in Review

Samlyn Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2017, closing a stake of 264,000 shares — an estimated $3.97M sold.

Samlyn Capital first reported a position in MNTA in Q4 2016 and held it in 1 quarter. The position peaked at $3.97M in Q4 2016. 162 funds tracked by Wall St. Rank hold MNTA as of Q1 2017.

  • Samlyn Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Samlyn Capital sold 264,000 Momenta Pharmaceuticals, Inc. shares in Q1 2017, an estimated $3.97M.
  • Samlyn Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Samlyn Capital's Momenta Pharmaceuticals, Inc. position peaked at $3.97M in Q4 2016.
  • 162 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2017.

Based on Samlyn Capital's 13F filing for Q1 2017, filed 15 May 2017.